Inion Oy
21 February 2007


    Inion CPS/OTPS FreedomPlate(TM) Receives 510(k) Regulatory Clearance for
Treating Wide Range of Orthopaedic Trauma Indications, including Ankle Fractures


Tampere, Finland and Takeley, UK. 21 February 2007...Inion (LSE: IIN.L), a
company focused on the development of novel biodegradable medical implants, has
received 510(k) regulatory clearance from the US Food and Drug Administration
(FDA) for the Inion CPS/OTPS FreedomPlate(TM) biodegradable device for surgical
application in fixation of fractures and osteotomies in the entire skeleton, but
excluding the spine. 510(k) clearance is required of medical device
manufacturers prior to commercial distribution in the US.

The INION CPS/OTPS FreedomPlate(TM) biodegradable implant system has been
cleared for the fixation of a wide range of bones, including those in the arm,
leg, skull and ankle, in the presence of appropriate additional immobilization
or fixation, such as plaster cast.

Importantly, this 510(k) clearance now allows Inion to sell its biodegradable
implant offering for all orthopaedic trauma indications, making it the first
complete biodegradable plating system. This also removes the previous limitation
of the Inion OTPS(TM) product line to target the high-value ankle fracture
segment of the trauma market in the USA, for which a biodegradable plating
system is currently undergoing a clinical trial to demonstrate its efficacy
compared to a metal construct.

Dr Auvo Kaikkonen, CEO of Inion, commented, "This is a very important new
product launch for Inion as it means we can market the Inion OTPS(TM) line for
all orthopaedic trauma indications in the USA, including for ankle fractures. We
will naturally continue with ongoing prospective randomised clinical multicentre
study of our Inion OTPS(TM) ankle system and expect results, i.e. clinical
efficacy data, by early 2008. We are sure that this clearance strengthens our
product offering and therefore our position in the orthopaedic surgery market."

The INION CPS/OTPS FreedomPlate(TM) implants are made of Inion Optima(TM)
biodegradable polymer blend, which have a long history of safe medical use and
that degrade in the body into carbon dioxide and water. The implants gradually
lose their strength during 18-36 weeks and bioresorption takes place within two
to four years.


A picture of the INION CPS/OTPS FreedomPlate(TM) is available on request.


                                     -Ends-


Inion Oy
Dr Auvo Kaikkonen, Chief Executive Officer                    Tel: +44 1279 874 222
Dr Kirk Andriano, VP of R&D                                   Tel: +44 1223 394 206

Citigate Dewe Rogerson                                        Tel: +44 207 638 9571
Mark Swallow / David Dible / Helena Galilee


About Inion (www.inion.com)

Inion Oy is a Finnish company that specializes in the development of
biodegradable medical implants.

The Inion core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes that are used to
enhance the healing of skeletal injuries (bone and soft tissue), such as those
caused by trauma or by reconstructive surgery. Inion implants are made from its
proprietary Inion Optima(TM) family of biomaterials, with properties tailored
for specific surgical applications, in terms of strength, flexibility and rate
of degradation.

Inion has developed and launched products in five strategic business areas -
cranio-maxillofacial surgery, orthopaedic trauma, sports medicine, dental
surgery and most recently in the spinal implant area - in nearly 50 countries
worldwide.

Inion was incorporated in early 2000 by an international team of experts in
biodegradable materials and their clinical applications, and listed on the
Official List of the UK Listing Authority in December 2004. The Company's has
operations in the UK, R&D and production facilities in Tampere, Finland, and a
US office in Oklahoma City, OK.

This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAIIFIAFSILFID
Inion Oy (LSE:IIN)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Inion Oy Charts.
Inion Oy (LSE:IIN)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Inion Oy Charts.